Research programme: polymyxins - The Medicines Company

Drug Profile

Research programme: polymyxins - The Medicines Company

Alternative Names: FADD-225; FADD-251; FADD-271; FADDI-085; FADDI-100; FADDI-124; FADDI-183; FADDI-239; FADDI-287

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Medicines Company
  • Class Polymixins
  • Mechanism of Action Cell membrane structure inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 16 Jul 2016 Preclinical trials in Bacterial infections in Australia (Intravenous route)
  • 16 Jul 2016 Preclinical trials in Pseudomonal infections in Australia (Intravenous route)
  • 16 Jul 2016 Antimicrobial data from a preclinical trial in Pseudomonal and bacterial infections presented at the ASM Microbe 2016 (ASM-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top